Concerned issues and controversies in perioperative immunotherapy for resectable non-small cell lung cancer.

Front Immunol · 2025 · PMC12705576 · PMID 41409285

Europe PMC DOI

hedged sentence

0.1400

closest p · 2.8× alpha

0.1400

boldest claim

The sentences

did not reach statistical significancep = 0.14not close (p > 0.1)

Nonetheless, for the subgroup with high PD-L1 expression (TPS ≥ 50%), the DFS advantage associated with pembrolizumab did not reach statistical significance (HR, 0.82; p = 0.14) ( 18 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.